Skip to content

A new drug for moderate-to-severe plaque psoriasis is now available in Malaysia

Learn more about the treatment of plaque psoriasis. STELARA is a prescription medicine approved to treat adults 18 years and older with moderate or severe plaque psoriasis that involves large areas or many areas of their body, who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills). Tell your doctor right away if you have any new or worsening medical problems including: headache, seizures, confusion, and vision problems. We are excited about the data presented at AAD as it adds to the body of evidence for oral tofacitinib in patients with moderate to severe plaque psoriasis. The robust data seen in the OPT Pivotal studies presented at this meeting provide important information on the profile of oral tofacitinib for moderate to severe psoriasis, and underscore that if approved, tofacitinib may offer a clinically meaningful option in oral therapy as the first potential treatment in a new class of medicines for this chronic condition, said lead investigator Kim A. Eli Lilly announced that the Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Taltz Approved for Moderate-to-Severe Plaque Psoriasis.

A    new    drug for moderate-to-severe plaque psoriasis is now available in Malaysia 20.05, an FDA-approved treatment for moderate to severe plaque psoriasis. Psoriasis patients commonly present with red/pink plaques of thickened, scaling skin. Examples of oral medications commonly used to treat psoriasis are methotrexate, acitretin and cyclosporine. It will depend on type of disease, severity, personal preferences, availability of the treatment and co-morbidities. Get the latest in biotechnology through daily news coverage as well as analysis, features, tutorials, webinars, podcasts, and blogs. Viropro has rights to manufacture the six products being developed by Oncobiologics, with Viropro holding exclusive commercialization rights to the six for Malaysia, while both companies will co-manage Viropro s Penang, Malaysia Alpha Biologics biomanufacturing subsidiary. Sandoz: GP2013 in two clinical trials now recruiting patients: Phase III ASSIST_FL study assessing biosimilar in treatment of patients with previously untreated Advanced Stage Follicular Lymphoma (NCT01419665), the company told ClinicalTrials.

Many therapeutic options are available for patients with psoriasis, ranging from topical agents to phototherapy and systemic and biologic agents. Although her psoriasis may have been mild in the past, it is now moderate-to-severe given the distress it is causing her and the large percentage of BSA it now covers. New York, NY: McGraw-Hill Medical; 2013. Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. Celgene has also developed orally available small molecules that inhibit the production of multiple pro-inflammatory mediators including interleukin-2 (IL-2), IL-12, interferon-gamma, TNF-alpha, leukotrienes, and nitric oxide synthase. In addition, apremilast is also indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). New Drugs Online Report for pomalidomide online February 2015. The drug, developed by Celltrion and which will be co-marketed by Pfizer, goes by the name Inflectra. NOW WATCH: Scientists are testing a new drug that could add years to your dog’s life.

Psoriasis Treatment Shampoo, Spray, And Lotion (clobetasol Propionate)

A    new    drug for moderate-to-severe plaque psoriasis is now available in Malaysia 3Atopic dermatitis is a severe form of eczema. Physicians told Leerink they were likely to prescribe the medication for adults with moderate to severe atopic dermatitis. Fernandez said he anticipates little competition for the new drug, which could be appropriate for 700,000 to 800,000 patients. Using the plaque-psoriasis market as a benchmark because of its similar size, Leerink estimated that a year of treatment would be priced between 15,000 and 20,000. After searching by disease, a list of available Celgene-sponsored trials will be displayed. (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis. Raptiva will no longer be available after June 8, 2009. Because of the potential for severe psoriasis worsening with abrupt discontinuation of Raptiva, it is important that patients talk with their doctor before stopping treatment. Genentech estimates that approximately 2,000 patients in the United States may currently be receiving Raptiva for chronic plaque psoriasis. The Raptiva prescribing information was further updated in March 2009 to include additional information on the risk of PML and a new Medication Guide for patients.

Current And Emerging Medications For Psoriasis